In the 28 patients with ALK+ NSCLC treated at 180 mg once daily with 7-day lead-in at 90 mg, median PFS was 16.3 months (95% CI: 9.2–27.5), with PFS rates of 18% (95% CI: 5–38) at 3 years and 9% (95% CI: 1–31) at 5 years (Table 1). This evidence concerns the gene ALK and non-small cell lung carcinoma.